Barclays PLC Increases Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Barclays PLC lifted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 7.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 298,445 shares of the biopharmaceutical company’s stock after purchasing an additional 20,880 shares during the period. Barclays PLC owned about 0.18% of ACADIA Pharmaceuticals worth $5,477,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. R Squared Ltd purchased a new stake in ACADIA Pharmaceuticals during the 4th quarter worth about $47,000. KBC Group NV lifted its stake in ACADIA Pharmaceuticals by 67.0% during the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 2,044 shares during the last quarter. Globeflex Capital L P acquired a new position in ACADIA Pharmaceuticals in the fourth quarter valued at approximately $168,000. Xponance Inc. purchased a new position in ACADIA Pharmaceuticals in the fourth quarter valued at approximately $186,000. Finally, Vinva Investment Management Ltd acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter worth approximately $187,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Stock Down 0.7 %

NASDAQ:ACAD opened at $14.73 on Friday. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $13.40 and a fifty-two week high of $20.68. The firm’s 50 day moving average is $16.64 and its two-hundred day moving average is $16.92. The company has a market cap of $2.46 billion, a P/E ratio of 18.88 and a beta of 0.54.

Insider Buying and Selling

In other news, EVP Mark C. Schneyer sold 2,708 shares of the firm’s stock in a transaction dated Tuesday, April 8th. The stock was sold at an average price of $14.82, for a total value of $40,132.56. Following the transaction, the executive vice president now directly owns 59,456 shares in the company, valued at $881,137.92. This trade represents a 4.36 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the sale, the director now owns 17,595 shares of the company’s stock, valued at $320,756.85. The trade was a 21.85 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 14,169 shares of company stock valued at $242,686. 28.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Guggenheim cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $23.00 to $20.00 in a report on Friday, January 3rd. StockNews.com raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 8th. Deutsche Bank Aktiengesellschaft began coverage on ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $23.93.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.